News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Discovery Laboratories to File Surfaxin Response in 4 Weeks
September 24, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Sept 24 (Reuters) - Discovery Laboratories Inc said it expects to submit a complete response to the U.S. Food and Drug Administration's concerns on its experimental lung drug for infants within the next four weeks.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Insights
Can Europe turn world-class science into world-class scale?
April 16, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Drug Development
Whitepaper: CDMOs at a Crossroads
April 15, 2026
·
1 min read
·
BioSpace Insights
Obesity
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
April 15, 2026
·
2 min read
·
Tristan Manalac
Podcast
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
April 15, 2026
·
1 min read
·
Heather McKenzie